Medical Research Council (MRC)
Small Molecule High-Throughput Screen Using AstraZeneca Facilities
16:00 UK time
Last updated:
Details
| Funder | Medical Research Council (MRC) |
| Budget | Up to £270,000 FEC (£250,000 cost to MRC) |
| Deadline | 28 January 2027 |
| Duration | 12-18 months (typically 15 months) |
| Consortium | Required - host research organisation with AstraZeneca providing screening facilities and technical input |
| Application | Single stage |
| Frequency | Annual |
| Eligible countries | GB |
Eligibility & scope
Supports academic researchers (excluding international research organisations and commercial-led applications) to discover small molecule drug starting points using AstraZeneca's compound library and HTS facilities. MRC funds up to four projects per year; researchers are encouraged to embed at AstraZeneca's Cambridge site for up to three months.
Similar grants
Therapeutic Catalyst
Cancer Research UKDeadline: 25 Sept 2026Up to £250k (Target Award) or up to £350k (Early Therapy Award)Therapeutic Catalyst - Early Therapy Award
Cancer Research UKDeadline: 25 Sept 2026Up to £350kDrug Development Project
Cancer Research UKTranslation MRC Impact Acceleration Awards
MRC (UKRI)Deadline: 11 Nov 2026£50k–£300k FEC (80% funded, i.e. up to £240k awarded)Therapeutic Catalyst - Target Award
Cancer Research UKDeadline: 25 Sept 2026Up to £250k
Browse Related
Could Small Molecule High-Throughput Screen Using AstraZeneca Facilities be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →